Spots Global Cancer Trial Database for A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Official Title: A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer
Study ID: NCT05022849
Conditions
Study Description
Brief Summary: The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
City of Hope Cancer Center, Duarte, California, United States
Norton Cancer Institute, Louisville, Kentucky, United States
University Of Minnesota, Minneapolis, Minnesota, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Columbia University Medical Center, New York, New York, United States
Levine Cancer Institute, Charlotte, North Carolina, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
Contact Details
Name: Janssen Research & Development, LLC Clinical Trial
Affiliation: Janssen Research & Development, LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
